Royalty Pharma plc RPRX

NAS: RPRX | ISIN: GB00BMVP7Y09 30/04/2025

32,82 USD (+0,34%)

(+0,34%) 30/04/2025

Grafiek Royalty Pharma plc

Grafiek Royalty Pharma plc

1 dag1d 0,34%
1 week1w 2,47%
1 maand1m 5,29%
3 maanden3m 4,76%
6 maanden6m 21,11%
1 jaar1j 16,92%
5 jaar5j -26,25%

donderdag 8 mei 2025, 13:00

Kwartaalcijfers (1ste kwartaal)

Royalty Pharma plc in het nieuws

Toon enkel gratis nieuws

9 januari 2023 · Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness · Persbericht

13 juli 2022 · Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value · Persbericht

30 juni 2022 · Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma · Persbericht

29 maart 2022 · Royalty Pharma Announces Charitable Alliance with The Leukemia & Lymphoma Society (LLS) To Advance Initiatives that Address Healthcare Disparities in Blood Cancer Care and Treatment · Persbericht

17 februari 2021 · Royalty Pharma Reports Q4 2020 and Full-Year Results · Persbericht

22 januari 2021 · Royalty Pharma to Announce Fourth-Quarter 2020 Financial Results on February 17, 2021 · Persbericht

8 januari 2021 · Royalty Pharma Announces 13% Dividend Increase · Persbericht

7 januari 2021 · Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 12 · Persbericht

Profiel Royalty Pharma plc

Gezondheidstechnologie

Medicinale en botanische productie

Website: www.royaltypharma.com

Hoofdzetel: New York, New York Verenigde Staten

CEO: Pablo Gerardo Legorreta

Werknemers: 92

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe